[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diagnosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diagnosis":32},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,46,0,25,[9,51,85,116,143,168,196,217,251,276,297,325,357,386,410,433,460,483,505,534,557,576,601,620,643],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100516585","intraoral-scanners-as-periodontal-and-dental-pathologies-diagnosis-tools-100516585",false,"NCT06006429","Intraoral Scanners as Periodontal and Dental Pathologies Diagnosis Tools","Digital Extraction and Scientific Visualization of Clinical Characteristics From 3D Data From Intraoral Scanners for Dental and Periodontal Pathologies Research : Computer Formalization and Feasibility Study","Odonto3D","Inclusion Criteria:\n\n* adultes\n* consulting the Dental Care Service of the university hospital of Reims\n* presenting at least one gingival recession\n* presenting at least 10 pairs of opposing teeth\n* speaking French\n* who signed the informed consent form\n* affiliated to the French Social Security system\n\nExclusion Criteria:\n\nPatients presenting :\n\n* pregnancy or breastfeeding\n* orthodontic treatments\n* patients under legal protection, trusteeship or guardianship\n* unable to understand auto-questionnary",true,"ALL","18 Years",{"count":22,"type":23},30,"ESTIMATED","INTERVENTIONAL",[26],"NA","Periodontal diseases and dental pathologies are highly prevalent oral diseases. Thirty-three to fifty percent of adult population presented at least one untreated caries and more than 50% of French population are affected by severe periodontitis. These diseases affect dental organ or periodontal attached system but could have negative impact on general health, quality of life, word and individual well-being. Association between chronic diseases as diabetes, rheumatoid arthritis, cardiovascular diseases, and oral health have been well investigated. Dental and periodontal diagnosis is dependent of various clinical parameters time consuming and dependent operator. It represents a public health challenge. Informatic analysis detecting diseases could be a time gain and a more precise diagnosis tool. Today, any software or algorithm allow automatized detection, clinical qualitative or quantitative indices recording while these informations are present in numeric models",[29,30,31,32],"Periodontitis","Gingivitis","Dental Caries","Diagnosis",[34,35,36,37],"Periodontal diseases","Dental caries","intra-oral camera","diagnosis","RECRUITING","2026-06-11",{"date":41,"type":42},"2026-06-12","ACTUAL",{"date":44,"type":42},"2022-05-11",{"date":46,"type":23},"2027-12-11",{"name":48,"class":49},"CHU de Reims","OTHER",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":67,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":50},"100639681","screening-characterization-and-longitudinal-follow-up-of-patients-with-cardiac-amyloidosis-100639681","NCT07577466","Screening, Characterization, and Longitudinal Follow-up of Patients With Cardiac Amyloidosis","Inclusion Criteria:\n\n* Age \\> 18 years\n* Male and female patients undergoing clinically indicated diagnostic work-up for amyloidosis or with a previously confirmed diagnosis of cardiac amyloidosis prior to initiation of therapy\n* Presence of left ventricular wall thickness \\> 12 mm on transthoracic echocardiography and at least one \"red flag\" suggestive of cardiac amyloidosis (according to ESC 2021 criteria) or an otherwise clinically established suspicion of amyloidosis\n* Written informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Contraindications to cardiac MRI (e.g., metallic foreign bodies, older-generation pacemakers, severe obesity, claustrophobia)\n* Lack of written informed consent for study participation\n* Inability to comply with the study procedures",{"count":58,"type":23},200,"OBSERVATIONAL","Cardiac amyloidosis is a progressive disorder caused by extracellular deposition of amyloid fibrils in the heart, leading to heart failure and impaired cardiac function. Early diagnosis and targeted therapies are essential to improve patient outcomes. This prospective, single-center study aims to longitudinally follow patients with suspected cardiac amyloidosis to characterize disease progression and assess treatment effects. Participants will undergo cardiac magnetic resonance imaging (resting and exercise stress MRI), magnetic resonance spectroscopy, cardiopulmonary exercise testing (spiroergometry) and blood testing at baseline and at 6, 12, and 24 months",[62,63,64,65,32,66],"Amyloidosis Cardiac","Heart Failure","Cardiac MRI","Spectroscopic Analysis","Phenotyping",[64,68,69,70,71,72,73,74],"Exercise MRI","Magnetic Resonace Spectroscopy","Spirometry","Cardiopulmonary Exercise Testing","Disease Progression","Treatment Monitoring","Longitudinal Study","NOT_YET_RECRUITING","2026-05-04",{"date":78,"type":42},"2026-05-11",{"date":80,"type":23},"2026-06-15",{"date":82,"type":23},"2029-12-31",{"name":84,"class":49},"Heinrich-Heine University, Duesseldorf",{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":19,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":96,"conditions":97,"keywords":101,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100593819","diagnosing-asthma-with-clinically-accessible-non-invasive-and-efficient-tests-a-child-inclusive-translational-investigation-100593819","NCT07011394","Diagnosing Asthma With Clinically Accessible, Non-invasive, and Efficient Tests: a Child-inclusive Translational Investigation","DIVE 2","Inclusion Criteria:\n\n* Individuals aged 6 to \\\u003C18 years, presenting symptoms suggestive of asthma\n* Patients referred for a methacholine bronchial provocation test by primary care (defined as non-pulmonologist, non-ENT specialist, non-allergist)\n* Spirometry inconclusive\n\nExclusion Criteria:\n\n* Use of an inhaled or systemic corticosteroid in the previous 48 hours;\n* Smoking in the previous 6 hours; history of viral and\u002For bacterial respiratory infection in the past 4 weeks;\n* major cardiopulmonary disease, including: a) chronic obstructive pulmonary disease (COPD), defined by all of the following: i) aged ≥ 40 years , ii) permanent obstruction on spirometry (FEV1\u002FFVC \\\u003C0.7) and iii) a smoking history of \\>10 pack-years or known alpha-1-antitrypsin deficiency, b) lung conditions deemed significant by the investigator, including cystic fibrosis and bronchiectasis, and c) unstable heart disease.","6 Years","17 Years",{"count":95,"type":23},123,"Asthma is a common inflammatory respiratory disease affecting 11% of Canadians, but its diagnosis remains challenging, leading to delays in treatment or overtreatment. Spirometry with a reversibility test and bronchial provocation testing (BPT), considered the gold standard, are the reference diagnostic methods. However, access to BPT is limited as it is performed in hospital settings.\n\nType 2 inflammation biomarkers, the fractional exhaled nitric oxide (FeNO) and blood eosinophils (EOS), represent a potential alternative. In addition to their prognostic and theragnostic value, these markers predict a good response to inhaled corticosteroids in individuals aged ≥ 6 years with asthma. However, their use remains restricted to pulmonologists in specialized clinics and is not recommended as a diagnostic tool in Quebec.\n\nDespite studies demonstrating their diagnostic value in specialized settings, these tests remain underexplored in primary care and insufficiently studied in children under 12 years.\n\nThe objective of ou study is to evaluate the relevance and performance of FeNO and blood eosinophils in the diagnosis of asthma in children referred in primary care with non-diagnostic spirometry.",[32,98,99,100],"Inflammation","Asthma in Children","Asthma",[102,103,104,105],"observationnal study","asthma diagnosis","FeNO and eosinophil blood count","children","2026-04-29",{"date":108,"type":42},"2026-05-06",{"date":110,"type":42},"2024-04-09",{"date":112,"type":23},"2027-07-01",{"name":114,"class":49},"Université de Sherbrooke",3,{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":142},"100540699","emergency-medicine-pulmonary-embolism-testing-multicentre-study-100540699","NCT06320236","Emergency Medicine Pulmonary Embolism Testing Multicentre Study","EMPET","Inclusion Criteria:\n\n* Emergency department patient who is tested by an emergency physician for PE\n\nExclusion Criteria:\n\n* Patient is \\\u003C 18 years of age\n* No documentation of whether PE is the most likely diagnosis\n* D-dimer is not tested or else not resulted during the emergency visit\n* The D-dimer level is known before documentation of whether PE is the most likely diagnosis\n* The D-dimer is ordered prior to the physician assessing the patient\n* The patient has previously registered that they opt out of all research at the participating site\n* The patient leaves against medical advice\n* The patient has had PE or deep vein thrombosis imaging (CT pulmonary angiogram, ventilation-perfusion scan or lower limb ultrasound) within prior 30 days\n* There is a new (non-PE) indication for anticoagulation\n* The patient was initiated on treatment for presumed PE prior to PE testing\n* The patient has previously been enrolled into the study\n* The patient has a prior history of lower extremity deep vein thrombosis without availability of a baseline ultrasound scan\n* The patient was transferred from another hospital organization\n* The patient does not reside in Ontario\n* The patient has no valid Ontario Health Insurance Plan card",{"count":124,"type":23},4000,"It is important to diagnose pulmonary embolism in a timely manner to prevent death and long-term disability. More than half a million people (4-5% of emergency department patients) are tested for pulmonary embolism, although the positive rate is low. Imaging for PE testing exposes patients to radiation, is expensive, adds time to the emergency visit, and can lead to a false positive diagnoses. Existing protocols aimed at reducing unnecessary pulmonary embolism imaging are complex and seldom used by emergency physicians. Too many patients undergo unnecessary pulmonary embolism imaging.\n\nA new tool (called Adjust-Unlikely) could safely reduce pulmonary embolism imaging in Canada. A research group composed of researchers, emergency physicians, and patients developed the Adjust-Unlikely clinical decision rule: a rule which has been customized for emergency physicians and emergency patients. Adjust-Unlikely is highly sensitive at the bedside, meaning there are very few false negative results.\n\nThe study aim is to prospectively validate Adjust-Unlikely pulmonary embolism testing in emergency patients with suspected pulmonary embolism.",[127,128,32],"Pulmonary Embolism","D-dimer",[128,127,130,131,132],"Adjust-Unlikely","Diagnostic","Emergency Medicine","2026-04-15",{"date":135,"type":42},"2026-04-20",{"date":137,"type":42},"2024-01-01",{"date":139,"type":23},"2027-09-30",{"name":141,"class":49},"Dr. Kerstin de Wit",4,{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":19,"minAge":151,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":50},"100632040","early-temporal-dynamics-of-optic-nerve-sheath-diameter-after-therapy-in-gca-100632040","NCT07508514","Early Temporal Dynamics of Optic Nerve Sheath Diameter After Therapy in GCA","Early Temporal Dynamics of Optic Nerve Sheath Diameter After Glucocorticoid Therapy in Giant Cell Arteritis","SONIC-TIME","Inclusion Criteria:\n\n1. Participants must be enrolled in SONIC-GCA and must have:\n\n   * completed the baseline optic nerve sheath ultrasound\n   * confirmed GCA as determined by the baseline standardized GCA assessment in SONIC-GCA.\n2. Exposure to glucocorticoids for ≤ 48 hours and ≤ 160 mg prednisone-equivalent before baseline.\n3. Ability and willingness to provide written informed consent.\n4. Agreement to complete the SONIC-TIME intensive follow-up schedule.\n\nExclusion Criteria:\n\n1\\) Concurrent participation in a blinded interventional pharmaceutical clinical trial.","50 Years",{"count":153,"type":23},60,"Giant cell arteritis (GCA) is an inflammatory disease of large and medium arteries that can cause irreversible vision loss. Glucocorticoids (GCs) rapidly suppress inflammation, but diagnostic imaging tests such as temporal artery ultrasound or biopsy often become falsely negative within days of treatment. The optic nerve sheath diameter (ONSD), measurable by ocular ultrasound, reflects perineural edema and may serve as a quantitative biomarker of ocular inflammation in GCA.\n\nThe SONIC-TIME study (Early Temporal Dynamics of Optic Nerve Sheath Diameter After Glucocorticoid Therapy in Giant Cell Arteritis) is a single-center, prospective observational substudy embedded within SONIC-GCA (NCT05749094) at Hôpital du Sacré-Cœur de Montréal. It aims to characterize how rapidly ONSD decreases after GC initiation and how this trajectory relates to cumulative GC exposure, intravenous methylprednisolone, and early use of steroid-sparing therapies.\n\nSixty participants with newly diagnosed GCA will undergo serial optic nerve sheath ultrasound, blood tests (CRP, ESR), and when feasible, temporal artery ultrasound over the first two months of therapy (Days 3, 7, 10, 14, 21, 28, and Month 2). No experimental treatments are given; all participants receive standard-of-care therapy.\n\nThe primary objective is to quantify the percent change in mean ONSD from baseline to Day 28. Secondary objectives include modeling ONSD change over time, assessing associations with cumulative steroid dose and inflammatory markers, and estimating the time to normalization below the SONIC-GCA cutoff. Findings will define the optimal imaging window and refine the diagnostic and monitoring role of optic nerve ultrasound in GCA.",[156,157,158,32],"Giant Cell Arteritis","Temporal Arteritis","Optic Nerve Diseases","2026-03-31",{"date":161,"type":42},"2026-04-02",{"date":163,"type":23},"2026-05-01",{"date":165,"type":23},"2028-05-01",{"name":167,"class":49},"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal",{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":18,"sex":19,"minAge":176,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":24,"phases":180,"briefSummary":181,"conditions":182,"keywords":186,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":50},"100621946","social-cognition-screening-100621946","NCT07377227","Social COgnition Screening","Evaluation of Social Cognition: A New Screening Approach for Autism","ECoS-A","Inclusion Criteria:\n\n* ASD Group:\n* Boys or girls diagnosed with Autism Spectrum Disorder (based on clinical tools and observations)\n* Aged between 4 and 10 years old\n* Affiliation with a social security scheme\n* Informed consent of those with parental authority\n* DT Group:\n* Boys or girls\n* Aged between 4 and 10\n* Attending school in the Hauts-de-France region\n* Affiliation with a social security scheme\n* Consent of those with parental authority\n\nExclusion Criteria:\n\n* For ASD: Uncorrected visual or auditory impairments.\n* For DT: Intellectual disability, neurological or genetic disorders, autistic traits reported by teachers. The discrepancy between actual age and abilities calculated on the basis of standardised test scores","4 Years","10 Years",{"count":179,"type":23},128,[26],"Social cognition refers to the mental processes involved in social interactions, including social perception, motivation, communication, emotion recognition, and theory of mind. Face perception plays a key role in children's social development, but children with Autism Spectrum Disorder (ASD) tend to look less at social stimuli, especially faces, than typically developing (TD) peers. Eye-tracking studies highlight these visual exploration differences, linked to difficulties in joint attention, emotion recognition, and theory of mind, as well as in executive and memory functions. Standard diagnostic tests often require active participation and sufficient language, which makes assessment challenging for children with ASD and additional cognitive or language impairments.\n\nThis research project investigates how visual activity supports social cognition depending on cognitive and language levels, hypothesizing that eye-tracking can provide useful indicators for ASD screening and diagnosis.",[183,184,185,32],"Eye-tracking","Autism Spectrum Disorder","Social Cognition",[183,184,185,32],"2026-02-04",{"date":189,"type":42},"2026-02-06",{"date":191,"type":23},"2026-02",{"date":193,"type":23},"2028-12",{"name":195,"class":49},"Centre Hospitalier Universitaire, Amiens",{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":202,"enrollmentInfo":203,"targetDuration":205,"studyType":59,"phases":4,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":214,"leadSponsor":215,"locationsCount":50},"100619963","research-on-the-extraction-of-tongue-and-facial-diagnosis-features-of-psoriasis-vulgaris-in-traditional-chinese-medicine-and-its-correlation-with-laboratory-indicators-100619963","NCT07351448","Research on the Extraction of Tongue and Facial Diagnosis Features of Psoriasis Vulgaris in Traditional Chinese Medicine and Its Correlation With Laboratory Indicators","Inclusion Criteria:\n\n* Inclusion criteria for the non-psoriasis subjects: (1) Those who do not meet the Western medical diagnostic criteria for psoriasis; （2) No gender restrictions; 18 years old ≤ age ≤ 65 years old; (3) Understand and agree to participate in this study and sign the informed consent form; Inclusion criteria for the psoriasis blood stasis syndrome group: (1) Those who meet the Western medical diagnostic criteria for psoriasis and whose TCM syndrome classification belongs to blood stasis syndrome; (2) No gender restrictions; 18 years old ≤ age ≤ 65 years old; (3) Understand and agree to participate in this study and sign the informed consent form.\n\nInclusion criteria for the psoriasis non-blood stasis syndrome group: (1) Those who meet the Western medical diagnostic criteria for psoriasis and whose TCM syndrome classification belongs to blood heat syndrome\u002Fblood dryness syndrome; (2) No gender restrictions; 18 years old ≤ age ≤ 65 years old; (3) Understand and agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n* (1) Due to various reasons, the collected tongue and facial images may be unclear or cannot be successfully monitored and analyzed; (2) For those subjects whose facial makeup or tongue coating is applied, the information obtained from tongue and facial diagnosis may be inaccurate.","65 Years",{"count":204,"type":23},450,"2 Weeks","Psoriasis Vulgaris is a chronic, inflammatory, and immune-activated skin disease. It is the most common type of psoriasis, accounting for approximately 85-90% of all psoriasis patients. Its clinical features include erythema, papules, covered with varying scales, a long course of disease, and recurrent attacks. According to traditional Chinese medicine, psoriasis is mainly characterized by blood heat syndrome, blood stasis syndrome and blood dryness syndrome, accounting for more than 90% of all syndrome types. The TCM syndrome differentiation and treatment of psoriasis also attach great importance to the transformation and evolution of TCM syndrome types. For instance, the three syndrome types of blood heat syndrome, blood stasis syndrome and blood dryness syndrome are not static and can transform into each other. For example, blood heat syndrome can develop into blood dryness syndrome as the disease progresses, blood dryness syndrome can transform into blood stasis syndrome, and blood stasis syndrome can also transform into blood heat syndrome or blood dryness syndrome. Observation is an important diagnostic method in traditional Chinese medicine. The images of tongue and face diagnosis contain a lot of important clinical information. They can objectively reflect the prosperity and decline of qi and blood in the human body, the nature of diseases, the depth of the lesion location, the prognosis of the disease, and can also reflect the physiological and pathological changes of the body. In recent years, significant progress has been made in the research of digital and intelligent technologies for tongue and facial diagnosis. Introducing objective indicators such as tongue diagnosis, facial diagnosis and pulse diagnosis into the evaluation research of diseases has become a hot topic. This project, by analyzing the clinical tongue and facial image data of patients with psoriasis vulgaris and combining it with clinical laboratory indicators, fuses and analyzes the characteristic parameters of patients' tongue and facial diagnosis with blood biochemical indicators, metabolomics and other data. This is helpful to reveal the disease occurrence pattern of patients with blood stasis type psoriasis and construct a diagnostic model for blood stasis syndrome of psoriasis. At the same time, it provides a powerful decision support tool for clinical practice and also helps deepen our understanding of the complex process of the occurrence of blood stasis type psoriasis, thereby providing a solid scientific basis for formulating precise diagnostic and treatment strategies.",[208,209,32],"Psoriasis (PsO)","Traditional Chinese Medicine (TCM)","2026-01-12",{"date":212,"type":42},"2026-01-20",{"date":212,"type":23},{"date":139,"type":23},{"name":216,"class":49},"Shanghai Yueyang Integrated Medicine Hospital",{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":24,"phases":227,"briefSummary":228,"conditions":229,"keywords":233,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":50},"100620042","reasoning-enrichment-with-feedback-from-ia-in-nephrology-trial-100620042","NCT07352475","Reasoning Enrichment With Feedback From IA in NEphrology Trial","Reasoning Enhancement With Feedback From a Generative AI in Nephrology (REFINe): A Randomized Evaluation of Generative AI Support in Nephrology Diagnosis","REFINe","Inclusion Criteria:\n\nAdults aged 18 years or older.\n\nAble to read and answer clinical vignettes in English or French.\n\nAccess to a computer or smartphone with an internet connection.\n\nProvides informed consent online.\n\nParticipants are expected to have at least basic medical training (e.g., medical students, residents, fellows, or practicing clinicians), although no formal verification is required.\n\nExclusion Criteria:\n\nIndividuals under 18 years of age.\n\nInability to complete online study procedures.\n\nPrior involvement in the design, development, or evaluation of the AI system used in this study.",{"count":226,"type":23},100,[26],"The goal of this clinical trial is to learn how artificial intelligence (AI) may help doctors make diagnoses in kidney medicine. The researchers want to know whether an AI tool called a large language model (LLM) can help doctors choose the correct diagnosis more often and feel more confident in their answers.\n\nBefore starting the study, the research team tested several AI models and chose one of the best performers, a GPT-5-class model set to use high reasoning effort.\n\nThe main questions this study aims to answer are:\n\n1. Do doctors make more correct diagnoses when they can see AI suggestions?\n2. Does seeing AI suggestions change how confident doctors feel about their diagnosis?\n\nResearchers will compare doctors who receive AI suggestions with doctors who do not receive AI suggestions to see how the AI affects accuracy, confidence, and decision-making.\n\nParticipants will complete up to 10 online clinical cases. For each case, they will:\n\n1. Read a short medical scenario\n2. Suggest up to three possible diagnoses\n\n(If in the AI group) Review the AI's suggestions and decide whether to change their answer\n\nThe study will also look at how long participants take to answer each case and how the AI's performance compares to the human answers.",[32,230,231,232],"Clinical Decision-making","Artificial Intelligence (AI) in Diagnosis","Decision Support Systems, Clinical",[234,235,236,237,238,239,240,241,242,243],"Large Language Model (LLM)","Generative AI","Diagnostic Accuracy","Clinical Vignettes","Online Study","Randomized Controlled Trial","Nephrology Diagnosis","AI Clinical Decision Support","Human-AI Collaboration","Medical Reasoning",{"date":212,"type":42},{"date":246,"type":42},"2025-11-20",{"date":248,"type":23},"2026-12-31",{"name":250,"class":49},"University Hospital, Lille",{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":19,"minAge":151,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":24,"phases":260,"briefSummary":261,"conditions":262,"keywords":265,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":50},"100617789","evaluation-of-the-neomom-gastric-video-capsule-for-gastric-cancer-screening-100617789","NCT07323186","Evaluation of the NEOmom® Gastric Video Capsule for Gastric Cancer Screening","NEOTOGAS","Inclusion Criteria:\n\n* Male or female patient,\n* Aged between 50 and 74 inclusive with a life expectancy of at least 10 years,\n* Undergoing screening or surveillance colonoscopy (for colorectal cancer or polyps)\n* Patient who has received verbal and written information as well as a patient booklet on the VCE-CM examination and has given their written informed consent.\n* Patient affiliated with a social security scheme\n* Effective contraception throughout the study for women of childbearing age\n\nExclusion Criteria:\n\n* Patients who have had or currently have the following (items from the TOGAS pilot study\u002Fspecific to endoscope use) will not be included in the study:\n* An EOGD in a high-volume endoscopy centre within the last 3 years\n* Known gastric cancer\n* Known genetic cancer syndromes\n* Previous gastrectomy or bariatric gastric surgery\n* Known gastric precancerous condition (gastric atrophy, intestinal metaplasia, dysplasia)\n* Acute gastrointestinal haemorrhage in the last 4 weeks\n* A coagulation disorder or medication that prevents biopsy sampling\n* A risk associated with sedation or anaesthesia\n* Severe heart disease\n* An inability to actively consent to participation in the study, and patients under guardianship or legal protection.\n\nPregnant or breastfeeding patients will not be included.\n\nPatients with the following conditions (specific to VCE-CM examination) will not be included in the study:\n\n* Swallowing disorders or known gastroparesis\n* A history of digestive surgery\n* Clinical or radiological signs suggestive of narrowing of the digestive tract\n* An occlusive or sub-occlusive condition, a known or suspected history of stenosis or digestive fistula\n* Left heart failure with orthopnoea\n* Overweight (\\> 135 kg)\n* Reduced mobility (i.e. unable to transfer or move themselves)\n* Persons with pacemakers, defibrillators or metallic foreign bodies (with the exception of dental implants) will not be included in order to avoid interference with the robot.","74 Years",{"count":226,"type":23},[26],"Gastric cancer remains a major public health concern, with approximately 6,600 new cases diagnosed each year in France. Despite therapeutic progress, its overall prognosis is still poor: the 5-year survival rate across all stages remains below 30%. This survival is closely linked to the stage at diagnosis. Early-stage gastric cancer has an excellent prognosis, with survival rates above 90%, while advanced-stage disease shows survival below 10%. This dramatic contrast underscores the critical need to develop and implement approaches that enable earlier and more reliable diagnosis. Early detection is therefore one of the most powerful strategies to reduce mortality from this severe and often silent disease.\n\nWithin this context, the overall ambition of the NEOTOGAS project is to contribute to lowering gastric-cancer mortality by improving the ability to diagnose the disease at an early, more treatable stage. The project positions itself within the broader field of prevention, targeting one of the leading and most challenging public health issues. Gastric cancer is often a potentially fatal condition that typically develops over many years, most commonly as a consequence of chronic infection with Helicobacter pylori (H. pylori). Identifying precancerous gastric lesions before the appearance of invasive cancer thus represents a strategic priority for the healthcare system.\n\nOur central hypothesis is that a non-invasive, robot-assisted endoscopic approach using a magnetic-guided capsule-the NEOMOM system-will prove effective for detecting precancerous gastric lesions. If validated, this technology could form the foundation of an organized, large-scale screening program. Such a screening strategy would represent a major innovation, particularly in populations at higher risk due to H. pylori infection or other predispositions. The ability to offer a less invasive, more accessible examination could significantly increase screening adherence and facilitate earlier diagnosis.\n\nThe NEOTOGAS study is based on an innovative combination of technologies: a magnetic-guided videocapsule steered inside the stomach using the NEOMOM robot, supported by artificial intelligence to assist image acquisition and interpretation. The study aims to assess the level of concordance between lesion detection through the current gold-standard procedure (conventional endoscopy) and this new capsule-based examination. Beyond diagnostic performance, the project also integrates several essential dimensions for future implementation: patient acceptability of the procedure, overall cost, duration of the examination, and the potential clinical and organizational benefits of this alternative approach.\n\nA key component of the project is the creation of high-quality image banks. These will support the development of advanced AI models capable of enhancing lesion detection and ensuring the completeness of the stomach examination. Such resources will be instrumental in evaluating whether magnetic-guided capsule endoscopy could realistically be integrated into structured gastric cancer screening pathways in the future. The project therefore aims not only to evaluate a device, but also to explore its broader screening potential and its capacity to transform clinical practice.\n\nThe primary objective of the NEOTOGAS study is to rigorously assess the performance of this innovative medical device, which combines magnetic navigation with AI-assisted image interpretation, in detecting gastric lesions. The AI module plays a dual role: ensuring that the entire stomach is adequately explored and helping highlight images of interest for clinicians during analysis. By improving both completeness and accuracy, the technology could represent a significant advancement over existing non-invasive diagnostic tools.\n\nTo achieve these goals, the study plans to include a total of 100 patients over a 6-month period. This sample size will allow a robust comparison of diagnostic concordance while providing sufficient data to evaluate feasibility, patient experience, and operational parameters. The findings of NEOTOGAS will determine whether magnetic-guided capsule endoscopy can be considered a relevant and effective method for future organized gastric cancer screening programs.",[263,32,264],"Stomach Cancer","Endoscopy of Stomach (Procedure)",[266],"stomach cancer","2025-12-23",{"date":269,"type":42},"2026-01-07",{"date":271,"type":23},"2025-12-15",{"date":273,"type":23},"2026-06-07",{"name":275,"class":49},"Nantes University Hospital",{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":24,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":50},"100575641","clinical-ultrasound-a-new-link-between-town-and-hospital-in-seine-saint-denis-echo93-100575641","NCT06774924","\"Clinical Ultrasound, a New Link Between Town and Hospital in Seine-Saint-Denis\". (ECHO93)","ECHO93","Inclusion Criteria:\n\n1. Adult patient over 18 years of age\n2. Patient with signed informed consent\n3. Patient managed by:\n\n   * one of the structures involved (UDR\u002F SAU Jean Verdier, MSP Pantin, Cabinet Médical du Dr TAYBALY à Aulnay-sous-Bois) for referral to the UDR for rapid diagnosis (phases 1 and 2)\n   * the Health Bus (phase 3)\n\nExclusion Criteria:\n\n1. Patient on the UDR iron-deficiency anemia clinical pathway\n2. Patient deprived of liberty by judicial or administrative decision\n3. Patient who does not speak French and cannot benefit from the presence of a relative or translator (physical or online)\n4. Patient with a contraindication to the use of EchOPen:\n\n   * patients with a body mass index greater than 34.9 kg\u002Fm2\n   * life-threatening patients requiring emergency medical care.",{"count":226,"type":23},[26],"The ECHO93 study is a non-healthcare interventional study. Its aim is to evaluate the effect of introducing the echOpen probe into the management of patients referred to the Jean Verdier UDR, in terms of time to diagnosis.\n\nThe study is divided into 3 phases:\n\nPhase 1: opening of the Rapid Diagnosis Unit (UDR) at Jean Verdier Hospital Phase 2: Opening of the Jean Verdier Hospital UDR, MSP Pantin, Dr TAYBALY's medical practice in Aulnay-sous-Bois, one month after the start of phase 1.\n\nPhase 3: Opening of the Jean Verdier Hospital Health Bus, one month after the start of phase 2.",[32,287],"Clinical Ultrasound","2025-12-19",{"date":290,"type":42},"2025-12-26",{"date":292,"type":42},"2025-02-12",{"date":294,"type":23},"2026-09-30",{"name":296,"class":49},"Assistance Publique - Hôpitaux de Paris",{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":305,"minAge":20,"maxAge":151,"enrollmentInfo":306,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":308,"conditions":309,"keywords":315,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":50},"100499146","endometriosis---mri-100499146","NCT05779462","ENDOMETRIOSIS - MRI","Study of Pelvic Organ Mobility by Dynamic MRI in Pelvic Endometriosis","ENDO-MRI","Inclusion Criteria:\n\n* Patient referred for suspected pelvic endometriosis requiring pelvic MRI\n* Female, nulliparous,\n* patient with signed written consent, patient with health insurance,\n* patient willing to comply with all study procedures and duration\n\nExclusion Criteria:\n\n* BMI \\> 35,\n* history of hereditary collagen and elastic tissue disease,\n* history of pelviperitonitis,\n* history of major pelvic surgery,\n* inability to receive informed information,\n* inability to participate in the entire study,\n* lack of social security coverage,\n* refusal to sign consent","FEMALE",{"count":307,"type":23},52,"Endometriosis is a frequent pathology with an estimated prevalence of 10% of women of childbearing age. There is no exact correspondence between the symptoms described by the patients and the severity of the lesions, which makes clinical diagnosis difficult. It therefore seems important to improve the complementary examinations available to make the diagnosis more precise and to better study the effectiveness of the treatments implemented. The clinical examination and per-surgical findings of patients with deep pelvic endometriosis show a clear decrease in the mobility of the pelvic organs in relation to each other, but few studies have looked at this mobility, which could however have an implication in explaining the pathophysiology of the disease and the symptomatology of the patients, as well as in the detection of lesions preoperatively. The persistence of hypo-mobility could also help to understand treatment failures.",[310,311,312,32,313,314],"Endometriosis","Mobility Limitation","Magnetic Resonance Imaging","Pelvis","Comparative Study",[316,311,317,313,314],"Endometriosis ;","Magnetic Resonance Imaging, Cine","2025-12-18",{"date":290,"type":42},{"date":321,"type":42},"2023-05-23",{"date":323,"type":23},"2026-07",{"name":250,"class":49},{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":19,"minAge":151,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":336,"conditions":337,"keywords":340,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":50},"100499566","health-opportunities-and-promoters-of-equitable-screening-for-lung-cancer-100499566","NCT05784922","Health Opportunities and Promoters of Equitable Screening for Lung Cancer","Health Opportunities and Promoters of Equitable Screening for Lung Cancer (HOPES for Lung Cancer)","HOPES","Inclusion Criteria:\n\n* Must be 50-80 years old\n* Are a current or former smoker (quit within 15 years, or a cumulative smoking status of \\> 20 pack-years)\n* Not currently enrolled in Lung Cancer Screening\n* Must speak English or Spanish\n\nExclusion Criteria:\n\n* Has a clinical cognitive inability to provide informed consent for participation in the study or complete a brief survey\n* Currently diagnosed with lung cancer\n* Currently enrolled in lung cancer screening\n* Have participated in the focus groups discussions from Aim 1","80 Years",{"count":335,"type":23},2000,"The goal of this clinical trial is to promote lung cancer screening (LCS) uptake among Hispanic current and former smokers. The main questions it aims to answer are:\n\n* What barriers do current and former Hispanic smokers face in the identification and documentation of their smoking status?\n* How can digital delivery of an educational video promote LCS uptake among current and former Hispanic smokers?\n\nParticipants will receive an educational video about lung cancer screening and complete brief, self-reported surveys afterwards.",[338,339,32],"Lung Cancer","Smoking Behaviors",[341,342,343,344,345,346,347],"lung cancer screening","Hispanic outreach","educational intervention","digital health","smoking documentation","smoking history","health equity","2025-10-10",{"date":350,"type":42},"2025-10-14",{"date":352,"type":42},"2023-02-03",{"date":354,"type":23},"2028-01-31",{"name":356,"class":49},"Massachusetts General Hospital",{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":365,"minAge":20,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":24,"phases":368,"briefSummary":369,"conditions":370,"keywords":372,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":142},"100555885","fusion-or-cognitive-ultrasound-guided-biopsy-to-detect-prostate-cancer-100555885","NCT06517901","Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer","MRI-targeted Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer","FOCUS-PC","Inclusion Criteria:\n\n* Men undergoing prostate biopsy (either transrectal or transperineal) for suspected prostate cancer as part of their regular medical care\n* Must be eligible to undergo both prostate biopsy procedure (cognitive or fusion)\n* Men undergoing their first prostate biopsy procedure or with no previous prostate biopsy within 3 years\n* Pre-biopsy mp-MRI of prostate with one or more lesions classified as PIRADS 3-5\n* Largest dimension of any lesion on mp-MRI to be ≤ 2 cm\n* Prostate-specific antigen level ≤ 20 ng\u002FmL and\u002For abnormal digital rectal examination\n\nExclusion Criteria:\n\n* mp-MRI detected lesions that are \\> 2 cm\n* History of prostate biopsy within 3 years\n* Previous diagnosis of prostate cancer\n* Contraindications to prostate biopsy (eg, fever, evidence of genito-urinary infection, excessive co-morbidities as per treating physician)","MALE",{"count":367,"type":23},1306,[26],"The MRI-targeted biopsy for prostate cancer detection can be performed using one of two techniques:\n\n1. Software-based fusion of MRI and ultrasound images (software fusion) or\n2. Visually estimated MRI-informed (cognitive fusion) technique\n\nTo date, there is a lack of adequately powered RCTs directly comparing the cognitive vs fusion targeted biopsy. This randomized study will directly compare the detection rates of clinically significant prostate cancer following either the cognitive or the fusion targeted prostate biopsy in men with suspicious lesions noted on multi-parametric MRI (mp-MRI) of prostate.",[371,32],"Prostate Cancer",[373,374,375,32,376],"Prostate","Cancer","Biopsy","MRI","2025-09-30",{"date":379,"type":42},"2025-10-03",{"date":381,"type":42},"2025-04-18",{"date":383,"type":23},"2027-06-30",{"name":385,"class":49},"Albany Medical College",{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":18,"sex":19,"minAge":393,"maxAge":394,"enrollmentInfo":395,"targetDuration":4,"studyType":24,"phases":396,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":50},"100533370","augmented-reality-for-mri-guided-interventions-100533370","NCT06224933","Augmented Reality For MRI-Guided Interventions","Augmented Reality Real-Time Guidance for MRI-Guided Interventions","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, ages 3 to 21\n* Patient referred to Interventional Radiology for image-guided needle injection, aspiration, or biopsy.\n\nExclusion Criteria:\n\n* Patients who are unable to give informed consent themselves or through their parents.\n* Patients under 3 years of age\n* Patients over 300 pounds.\n* Patients who are claustrophobic and unable to tolerate MRI-guided procedure.\n* Contraindications to MRI such as MR-unsafe implants.","3 Years","21 Years",{"count":7,"type":23},[26],"The purpose of this study is to determine feasibility and safety of using an augmented reality system in patients undergoing MRI-Guided needle procedures.",[399,400,32],"Infections","Pain","2025-08-28",{"date":403,"type":42},"2025-09-05",{"date":405,"type":42},"2024-02-06",{"date":407,"type":23},"2026-05-31",{"name":409,"class":49},"Children's National Research Institute",{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":429,"leadSponsor":431,"locationsCount":50},"100603611","role-of-mri-in-the-early-diagnosis-and-management-of-acute-stroke-and-its-impact-on-turnaround-time-in-emergency-settings-100603611","NCT07138768","Role of MRI in the Early Diagnosis and Management of Acute Stroke and Its Impact on Turnaround Time in Emergency Settings","The Role of MRI in the Early Diagnosis and Management of Acute Stroke and Its Impact on Turnaround Time (TAT) in Emergency Settings","Inclusion Criteria:\n\n* Age ≥18 years.\n* Both sexes.\n* Patients with acute stroke who are admitted to the emergency department.\n\nExclusion Criteria:\n\n* Contraindications to magnetic resonance imaging (MRI) or computed tomography (CT).\n* Symptoms strongly suggestive of subarachnoid hemorrhage.\n* Initiation of antithrombotic or thrombolytic treatment before the completion of both scans.\n* Inability to complete both scans in time to allow thrombolytic treatment within three h of the onset of symptoms.\n* Uncontrollable hypertension.\n* Pregnant or lactating women.",{"count":418,"type":23},136,"This study aims to evaluate the role of stroke protocol in the early diagnosis and management of acute stroke and its effect on turnaround time (TAT) in emergency settings.",[312,32,421,422,423,424],"Management","Acute Stroke","Turnaround Time","Emergency Settings","2025-08-23",{"date":427,"type":42},"2025-08-26",{"date":425,"type":42},{"date":430,"type":23},"2026-12-01",{"name":432,"class":49},"Tanta University",{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":439,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":19,"minAge":441,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":24,"phases":444,"briefSummary":445,"conditions":446,"keywords":449,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":50},"100596914","the-rightcall-implementing-a-sepsis-diagnostic-toolkit-to-improve-pediatric-diagnosis-in-ed-transfer-calls-100596914","NCT07051668","The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls","The Right Call: Implementing a Sepsis Diagnostic Safety Toolkit in a Pediatric Transfer Call Center to Improve Diagnosis of Children in General Emergency Settings","RightCall","Inclusion Criteria:\n\n* Patients transferred to Children's Hospital Colorado (CHCO) for emergency or inpatient care, as identified in the extant CHCO transfer center database AND in the extant CHCO quality improvement sepsis database AND one of the following:\n* Patients who met Phoenix sepsis criteria 1) in the referring ED, 2) during transport, 3) in the first 6 hours after arrival at the pediatric hospital, or 4) patients who developed Phoenix sepsis within 24 hours of arrival at the Children's Hospital underwent independent physician review by three emergency physicians. Patients in whom all three physicians agreed sepsis was most likely present, using the structured SaferDx tool were included\n\nExclusion Criteria:\n\n* Patients less than one month of age\n* Patients whose transfer call recording was not available in the database","1 Month",{"count":443,"type":23},500,[26],"Sepsis is a leading cause of death in children, and an early diagnosis that improves outcomes is less likely in children who are treated in general Emergency Departments (EDs), that treat adults and children, compared to pediatric Emergency Departments. The study team, in collaboration with invested clinicians and expert partners, has developed a pediatric sepsis diagnostic safety toolkit that we will implement in a pediatric health system's transfer call center. Preparation for launch of the toolkit will include education throughout Children's Hospital Colorado (CHCO), with a focus on transfer center nurses and accepting CHCO physicians who will be partnering in delivering the toolkit. Usual avenues for clinical education will be used, including meetings, endorsement from clinical leaders, emails, and physical materials such as badge and pocket cards. Referring Emergency Department (ED) providers outside of CHCO will not receive education about the toolkit by design, since they are the recipients of the toolkit which is designed to disseminate sepsis diagnostic knowledge in real time to general EDs within existing transfer workflows. This research will test whether the toolkit improves early pediatric sepsis diagnosis in general EDs where most children receive their first critical hours of care.",[447,32,448],"Sepsis","Emergencies",[450],"Pediatric, Diagnosis","2025-08-12",{"date":453,"type":42},"2025-08-15",{"date":455,"type":42},"2025-07-08",{"date":457,"type":23},"2027-07-31",{"name":459,"class":49},"University of Colorado, Denver",{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":50},"100601302","non-invasive-diffusion-weighted-imaging-with-mrcp-in-the-diagnosis-of-neoplastic-biliary-obstruction-100601302","NCT07108725","Non-invasive Diffusion-weighted Imaging With MRCP in the Diagnosis of Neoplastic Biliary Obstruction","The Role of Non-invasive Diffusion-weighted Imaging With MRCP in the Diagnosis of Neoplastic Biliary Obstruction","Inclusion Criteria:\n\n* Adult patients (≥18 years) with clinically suspected biliary obstruction (e.g., jaundice, elevated liver enzymes, cholestasis).\n* Patients who are scheduled for magnetic resonance cholangiopancreatography (MRCP) and have undergone conventional imaging \\[ultrasound or computed tomography (CT)\\].\n* Patients who will undergo further invasive procedures, e.g., endoscopic retrograde cholangiopancreatography (ERCP), biopsy.\n\nExclusion Criteria:\n\n* Patients with contraindications to magnetic resonance imaging (MRI) (e.g., pacemakers, metal implants).\n* Patients who have previously undergone major biliary surgery or stent placement.\n* Pregnant or lactating women.",{"count":226,"type":23},"This study aims to evaluate the diagnostic value of non-invasive diffusion-weighted magnetic resonance imaging (DW-MRI) in detecting neoplastic biliary obstruction.",[470,471,32,472],"Non-invasive Diffusion-weighted Imaging","Magnetic Resonance Cholangiopancreatography","Neoplastic Biliary Obstruction","2025-07-31",{"date":475,"type":42},"2025-08-07",{"date":477,"type":42},"2025-05-01",{"date":479,"type":23},"2025-12-01",{"name":481,"class":482},"The General Authority for Teaching Hospitals and Institutes","NETWORK",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":491,"conditions":492,"keywords":494,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":503,"locationsCount":50},"100575709","total-infectome-characterization-of-eye-infections-100575709","NCT06775808","Total Infectome Characterization of Eye Infections","Total Infectome Characterization of Eye Infections: a Metagenomic Sequencing Based Observational Study","Inclusion Criteria:\n\n1. Patients with a clinical diagnosis of one or more types of eye infections (including acute conjunctivitis, keratitis, uveitis, and endophthalmitis).\n2. Biological samples has been collected for clinical microbiological examination, or consented to participate in this study.\n\nExclusion Criteria:\n\n1\\. Patients who have no historically clinical surplus specimens.",{"count":58,"type":23},"Multiple pathogens can cause eye infection. In recent years, emerging and resurging viral infections represent an important public health problem. Many emerging viruses cause infectious diseases involving ophthalmic manifestations, including Mpox virus, Zika, Ebola, and SARS-CoV-2. Broad and unbiased pathogen surveillance is essential, so we design this unbiased metagenomic sequencing based study to investigate the total infectome of eye infections. The study is historical and prospective in design.",[493,32],"Eye Infections",[495,496],"infectome","metagenomic sequencing","2025-07-14",{"date":499,"type":42},"2025-07-17",{"date":501,"type":42},"2024-12-25",{"date":248,"type":23},{"name":504,"class":49},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":24,"phases":514,"briefSummary":515,"conditions":516,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":50},"100590208","raman-spectroscopy-in-the-diagnosis-of-extrahepatic-cholangiocarcinoma---a-pilot-study-100590208","NCT06964425","Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma - a Pilot Study","Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma","Inclusion Criteria:\n\n* person older than 18 years, who has known extrahepatic cholangiocarcinoma and is indicated for ERCP\n\nExclusion Criteria:\n\n* disagreement with the study",{"count":513,"type":23},20,[26],"Diagnosis of extrahepatic cholangiocarcinoma is challenging because the yield of imaging and tissue sampling is limited. Raman spectroscopy is an optical method based on the analysis of scattered monochromatic light. Raman spectroscopy is able to provide a molecular 'fingerprint' of the tissue to determine its type. The aim of this pilot study was to develop a methodology for in vivo Raman spectroscopy in bile ducts to improve the current diagnostic capabilities of extrahepatic cholangiocarcinoma.",[517,518,519,32,520,521,522,523,524],"Cholangiocarcinoma, Extrahepatic","Cholangiocarcinoma of the Extrahepatic Bile Duct","Cholangiocarcinoma, Perihilar","Raman Spectroscopy","Klatskin Tumor","Endoscopy","Biliary Stricture","Malignant Biliary Stricture","2025-06-29",{"date":527,"type":42},"2025-07-02",{"date":529,"type":42},"2023-02-04",{"date":531,"type":23},"2025-07-30",{"name":533,"class":49},"University Hospital Olomouc",{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":541,"enrollmentInfo":542,"targetDuration":544,"studyType":59,"phases":4,"briefSummary":545,"conditions":546,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":555,"locationsCount":50},"100522154","development-of-novel-gastric-cancer-screening-and-diagnosis-technologies-using-tongue-imaging-and-study-of-tongue-image-changes-mechanisms-100522154","NCT06078930","Development of Novel Gastric Cancer Screening and Diagnosis Technologies Using Tongue Imaging and Study of Tongue Image Changes Mechanisms","A Multi-center Observational Clinical Study on the Development of Artificial Intelligence-Based Gastric Cancer Screening and Diagnosis Technology Using Multi-Omics Analysis of Tongue Imaging and Tongue Coating","Inclusion Criteria for Gastric Cancer Patients:\n\n* 18≤age≤90\n* Histologically or cytologically confirmed gastric cancer\n* No prior chemotherapy, radiotherapy, biotherapy, immunotherapy or other anti-tumor treatment for gastric cancer\n* Subject volunteers to join the study, Signs informed consent, has good compliance and can cooperate with follow-up\n\nExclusion Criteria for Gastric Cancer Patients:\n\n* Two or more kinds of malignant tumors at the same time\n* Gastric cancer that has been treated by chemotherapy, radiotherapy, biotherapy, immunotherapy or other anti-tumor therapy\n* The use of glucocorticoids and antibiotics in the past three months\n* History of long-term medication\n* Presence of oral diseases such as tooth and gum diseases\n* Subjects who had other factors that might force them to terminate the research ahead of time, such as the development of other severe disease (including mental disease) that required combined treatment, seriously abnormal laboratory examination value, and family or social factors that might affect the subject safety or experimental data collection, as judged by the researchers\n\nInclusion Criteria for Healthy Participants:\n\n* 18≤age≤90\n* Willingness to participate in the study, signing an informed consent form, and demonstrating good compliance\n\nExclusion Criteria for Healthy Participants:\n\n* History of malignant tumors\n* The use of glucocorticoids and antibiotics in the past three months\n* History of long-term medication\n* Presence of oral diseases such as tooth and gum diseases\n* Subjects who had other factors that might force them to terminate the research ahead of time, such as the development of other severe disease (including mental disease) that required combined treatment, seriously abnormal laboratory examination value, and family or social factors that might affect the subject safety or experimental data collection, as judged by the researchers","90 Years",{"count":543,"type":23},100000,"5 Years","In this study, the investigators will prospectively recruit 100,000 individuals, including gastric cancer patients who have not undergone any anti-tumor treatment and non-gastric cancer participants. The investigators will construct a diagnostic model for malignant tumors based on the combination of tongue imaging, tongue coating, saliva, gastric juice, and fecal multi-omics data (including metagenomics, proteomics, metabolomics, etc.). Additionally, the study will explore the relationship between oral, gastric, and intestinal microbiota and the development of malignant tumors.",[547,548,32],"Gastric Cancer","Tongue Images","2025-05-29",{"date":551,"type":42},"2025-06-04",{"date":553,"type":42},"2021-06-01",{"date":248,"type":23},{"name":556,"class":49},"Zhejiang Cancer Hospital",{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":541,"enrollmentInfo":563,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":565,"conditions":566,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":50},"100593290","the-study-on-the-accuracy-of-peri-implant-probing-and-related-influencing-factors-100593290","NCT07004517","The Study on the Accuracy of Peri-implant Probing and Related Influencing Factors","Inclusion Criteria:\n\n1. Age greater than 18 years.\n2. The implant has completed osseointegration and has undergone final restoration for at least one month.\n3. The final restoration needs to be removed or retrieved for various reasons.\n\nExclusion Criteria:\n\n* Patients with serious systemic diseases, severe intraoral infections, severe mental disorders, pregnancy\u002Flactation in women, or other conditions that make oral treatment operations unsuitable.\n* History of crown removal or re-restoration within the past month prior to the visit.\n* The prosthesis has fallen off or is severely damaged and has lost its original form before the visit.\n* The prosthesis cannot be completely removed.\n* Refusal to participate in this study.",{"count":564,"type":23},83,"The aim of the diagnostic accuracy study was to compare the diagnostic accuracy of probing depth before (PPD-1) and following (PPD-2) the removal of prothesis in identifying the presence of peri-implantitis and assess the factors influencing peri-implant probing.",[567,32],"Peri-Implantitis","2025-05-26",{"date":551,"type":42},{"date":571,"type":42},"2024-01-11",{"date":573,"type":23},"2025-08",{"name":575,"class":49},"The Dental Hospital of Zhejiang University School of Medicine",{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":582,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":365,"minAge":176,"maxAge":333,"enrollmentInfo":584,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":586,"conditions":587,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":600},"100537477","x-linked-moesin-associated-immunodeficiency-100537477","NCT06278337","X-linked Moesin Associated Immunodeficiency","Etude Multicentrique Internationale rétrospective Des Patients Atteints de déficit Immunitaire associé à la moésine lié au Chromosome X (X Maid Pour X-linked Moesin Associated Immunodeficiency)","X-MAIDReg","Inclusion Criteria:\n\n* Male patient with a mutation in the MOESIN gene (MSN)\n* No objection to the collection of personal health data\n\nExclusion Criteria:\n\n\\-",{"count":585,"type":23},16,"Moesin deficiency was initially described in 7 male participants aged 4 to 69 years and is characterized by lymphopenia of the 3 lineages and moderate neutropenia. Genetically, 6 out of 7 participants had the same missense mutation in the moesin gene located on the X chromosome. The 7th patient has a mutation leading to the premature introduction of a STOP codon into the protein.Clinically the 7 participants with X-linked moesin-associated immunodeficiency all presented with recurrent bacterial infections of the respiratory, gastrointestinal or urinary tracts, and some had severe varicella.Therapeutically, in the absence of a molecular diagnosis and due to his SCID-like phenotype, one patient was treated with geno-identical hematopoietic stem cell transplantation . The remaining are untreated or treated with immunoglobulin substitution and\u002For prophylactic antibiotics.\n\nSince this study, the moesin gene has been integrated into DNA chips used for the molecular diagnosis of immune deficiencies in several countries. Physicians in Canada, the United States, Japan, South Africa and Europe have contacted us with a total of 16 known participants to date. Because of their very low severe, uncontrolled CMV infection and the absence of treatment recommendations, two 2 American participants were treated with allogeneic transplantation with severe post-transplant complications (1), and one of the participants died as a result of the transplant. Management of XMAID participants therefore varies widely from country to country, depending on age at diagnosis and clinical picture. It ranges from no treatment treatment (associated with recurrent infections and skin manifestations), IgIv substitution and\u002For antibiotic prophylaxis antibiotic prophylaxis, with low toxicity and apparent efficacy, and allogeneic transplantation, with all the risks risks involved (graft-related toxicity, graft versus host, disease, rejection, risk of infection). The Investigators therefore feel it is important to review the diagnosis, clinical presentation and management of X-MAID participants. The study the investigator propose will enable to understand the presentation of X-MAID participants, establish guidelines and provide the best treatment for each patient according to his or her clinical picture",[588,589,399,32],"Immune Deficiency","Autoimmune Diseases","2025-04-23",{"date":592,"type":42},"2025-04-25",{"date":594,"type":42},"2021-08-12",{"date":596,"type":23},"2027-01-12",{"name":598,"class":599},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",10,{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":605,"acronym":4,"eligibilityCriteria":606,"healthyVolunteers":12,"sex":365,"minAge":20,"maxAge":4,"enrollmentInfo":607,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":608,"conditions":609,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":50},"100588850","exploring-the-correlation-between-mri-image-characteristics-and-diagnosis-pathology-and-prognosis-in-patients-with-prostate-lesions-100588850","NCT06946771","Exploring the Correlation Between MRI Image Characteristics and Diagnosis, Pathology and Prognosis in Patients With Prostate Lesions","Inclusion Criteria:\n\n1. Patients with abnormal prostate-specific antigen (PSA) elevated (\\>4.0 ng\u002Fml) or abnormal digital rectal examination (DRE) or suspicious lesions found by prostate ultrasound, CT or MRI in the hospital\n2. Age\u002FGender: Adult male\n3. Patients who voluntarily participate in clinical trials and sign a written informed consent form for subjects\n\nExclusion Criteria:\n\n1. Patients with pacemakers, unknown materials, metal implants in the body, neurostimulators, and claustrophobia\n2. Patients who underwent biopsy, local ablation, prostate surgery, or endocrine therapy, chemotherapy, radiotherapy and other anti-tumor treatments before examination",{"count":443,"type":23},"Globally, prostate cancer is the second most common malignant tumor and the fifth leading cause of cancer-related death in men. In China, there will be more than 125,000 new cases of prostate cancer in 2022, ranking sixth in the incidence of male cancers, causing about 56,000 deaths, ranking tenth among male malignancies. The gold standard for the diagnosis of prostate cancer is prostate biopsy. In the past, whether to initiate a biopsy procedure depended on the screening results of abnormal prostate cancer, namely, elevated serum PSA levels (\\>4.0 ng\u002FmL) and abnormal digital rectal examination (DRE), but the low accuracy led to a large number of negative biopsy results, overdiagnosis and overtreatment of indolent tumors, causing many patients to undergo unnecessary biopsies, resulting in a large social burden.\n\nMagnetic resonance imaging (MRI) has been widely used in clinical practice due to its advantages of high soft tissue resolution, multi-plane, multi-sequence, multi-parameter imaging and no ionizing radiation. Studies have shown that multiparametric MRI (mpMRI), including T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), and dynamic contrast enhancement (DCE), can help select patients for initial biopsy and improve the detection rate of biopsy.\n\nMRI plays a vital role in the clinical diagnosis and treatment of prostate lesions. However, prostate MRI examinations often show \"same disease, different images\" and \"different diseases, same images\". Benign prostate lesions can simulate the characteristics of malignant lesions to interfere with the image and the judgment of clinicians, resulting in misdiagnosis and mistreatment. For example, inflammation in the peripheral zone of the prostate, like tumors, appears as low signal on T2WI, and hyperplastic nodules in the transition zone may also appear as restricted diffusion on DWI like tumors. Therefore, the complementary addition of different parameter sequences and the comprehensive judgment of qualitative and quantitative characteristics are very important for accurate diagnosis.\n\nWith the development of magnetic resonance technology, new imaging sequences continue to emerge, which can not only show the anatomical decomposition of the prostate more clearly, but also reflect the characteristics of the lesions from the pathological and physiological perspectives such as function, metabolism, and blood perfusion, and can better characterize prostate lesions.\n\nThe purpose of this study is to study the routine and functional MR imaging data of patients with prostate lesions in our institution, use pathology as the gold standard, and use image processing software to conduct qualitative and quantitative analysis of body composition, imaging characteristics, peritumoral tissue characteristics, and lymph node characteristics, so as to achieve benign and malignant differentiation, pathological feature prediction, and prognosis evaluation, in order to better perform accurate diagnosis, clinical decision-making, and prognosis evaluation in patients with prostate lesions.",[610,376,32],"Prostate Carcinoma","2025-04-20",{"date":613,"type":42},"2025-04-27",{"date":615,"type":42},"2025-02-25",{"date":617,"type":23},"2028-12-31",{"name":619,"class":49},"Zhen Li",{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":4,"eligibilityCriteria":626,"healthyVolunteers":12,"sex":19,"minAge":627,"maxAge":4,"enrollmentInfo":628,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":630,"conditions":631,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":634,"lastUpdatePostDateStruct":635,"startDateStruct":637,"completionDateStruct":639,"leadSponsor":641,"locationsCount":50},"100507586","assessing-cancer-treatment-response-to-therapy-using-18f-fspg-pet-100507586","NCT05889312","Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET","Improving Response Assessment in Cancer by Measurement of Cellular Redox Status Using 18F-FSPG Positron Emission Tomography","Inclusion Criteria:\n\n1. Written informed consent\n2. Aged 16 or above\n3. Histologically confirmed HNSCC or NSCLC, who are treatment naïve and scheduled to commence standard of care treatment ((chemo)radiotherapy)\n4. Willingness and ability to comply with scheduled study visits and tests\n5. Confirmation of adequate function of all major organs and systems\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. Concomitant uncontrolled medical conditions\n3. Participants likely to require palliative radiotherapy within the first 12 weeks of treatment\n4. Prognosis less than 3 months\n5. Previous anti-cancer treatment (only treatment naïve patients eligible for inclusion)","16 Years",{"count":629,"type":23},32,"Prospective single centre non-randomised exploratory observational study to measure changes in tumour cellular redox status with 18F-FSPG PET in stage 3 non-small cell lung cancer (NSCLC) and stage 3 and 4 head and neck squamous cell cancer (HNSCC) at baseline and during standard of care treatment, and to compare this with 18F-FDG PET\u002FCT and RECIST 1.1 response at 12 weeks.",[374,32,632,633],"Resistant Cancer","Response, Acute Phase","2025-04-02",{"date":636,"type":42},"2025-04-04",{"date":638,"type":42},"2025-02-19",{"date":640,"type":23},"2027-09",{"name":642,"class":49},"Guy's and St Thomas' NHS Foundation Trust",{"id":644,"slug":645,"hasResults":12,"nctId":646,"briefTitle":647,"officialTitle":648,"acronym":4,"eligibilityCriteria":649,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":650,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":652,"conditions":653,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":655,"lastUpdatePostDateStruct":656,"startDateStruct":658,"completionDateStruct":660,"leadSponsor":662,"locationsCount":50},"100518249","real-world-mapping-antithrombotic-regimens-in-mm-patients-on-treatment-100518249","NCT06028087","Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment","Real-World Mapping Antithrombotic Regimens in Multiple Myeloma Patients on Treatment (The MAMMOTH Study of the GIMEMA Working Party on Hemostasis and Thrombosis)","Inclusion Criteria:\n\n1. Age equal to or greater than 18 years of age.\n2. New diagnosis of symptomatic MM according to the CRAB or the SLIM criteria of the International Myeloma Working Group\n3. First active treatment for MM started after recruitment in the study\n4. Signed informed consent\n\nExclusion Criteria:\n\n1. Patients having had thrombosis within 6 months before diagnosis of MM\n2. Patients with need of combined antithrombotic regimens (i.e. VKA or DOAC or LMWK and one or two antiplatelet drugs)\n3. Ongoing first active treatment for MM initiated before the starting of the study.",{"count":651,"type":23},736,"The goal of this observational study is to learn about antithrombotic regimens in Multiple myeloma patients. The main question it aims to answer is the efficacy of different types of thromboprophylaxis (antiplatelet agents, heparins, oral anticoagulants) in preventing venous thromboembolism (VTE).",[654,32],"Multiple Myeloma","2025-03-12",{"date":657,"type":42},"2025-03-14",{"date":659,"type":23},"2025-03-10",{"date":661,"type":23},"2030-03",{"name":663,"class":49},"Gruppo Italiano Malattie EMatologiche dell'Adulto"]